Bernard M. Norcross, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
Indomethacin is the first nonsteroid drug with marked anti-inflammatory, antipyretic, and analgesic activity since the introduction of phenylbutazone in the early 1950's. This compound is more potent than either cortisol or phenylbutazone when assayed by the granuloma pouch inhibition and the carrageenin-induced edema-inhibition techniques.
More than 300 patients treated with Indomethacin during the past 2 years were observed for objective improvement and followed with extensive laboratory tests. The "side effects" included headaches, dizzyness, and gastrointestinal complaints.
Indomethacin was more effective and associated with less serious toxicity than phenylbutazone or adrenal corticosteroids in the long-term management of rheumatoid or osteoarthritic patients.
Learn more about subscription options.
Register Now for a free account.
Norcross BM. The Results of Indomethacin Therapy in Rheumatic Diseases.. Ann Intern Med. 1964;61:796. doi: 10.7326/0003-4819-61-4-796_1
Download citation file:
Published: Ann Intern Med. 1964;61(4):796.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only